
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.13 | -7.8313253012 | 1.66 | 1.7029 | 1.43 | 109482 | 1.49437149 | CS |
4 | 0.38 | 33.0434782609 | 1.15 | 1.94 | 1.09 | 258712 | 1.54285191 | CS |
12 | 0.29 | 23.3870967742 | 1.24 | 1.94 | 0.95 | 110464 | 1.43985802 | CS |
26 | -2.3241 | -60.3020160349 | 3.8541 | 3.95 | 0.95 | 119336 | 1.66583112 | CS |
52 | -2.73 | -64.0845070423 | 4.26 | 5.99 | 0.95 | 78926 | 2.27258789 | CS |
156 | -1.331 | -46.5221950367 | 2.861 | 9.6799 | 0.6706 | 325414 | 3.8420604 | CS |
260 | -19.47 | -92.7142857143 | 21 | 37.7 | 0.6706 | 568378 | 14.91391535 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions